Novo Nordisk (NVO) Stock Forecast, Price Target & Predictions
NVO Stock Forecast
Novo Nordisk stock forecast is as follows: an average price target of $159.00 (represents a 20.45% upside from NVO’s last price of $132.00) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
NVO Price Target
The average price target for Novo Nordisk (NVO) is $159.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $160.00 to $156.00. This represents a potential 20.45% upside from NVO's last price of $132.00.
NVO Analyst Ratings
According to 8 Wall Street analysts, Novo Nordisk's rating consensus is 'Buy'. The analyst rating breakdown for NVO stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Novo Nordisk Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Louise Chen | Cantor Fitzgerald | $160.00 | $135.23 | 18.32% | 21.21% |
| Aug 08, 2024 | Evan David Seigerman | BMO Capital | $160.00 | $126.17 | 26.81% | 21.21% |
| Jun 10, 2024 | Jasper Hellweg | Argus Research | $160.00 | $142.88 | 11.98% | 21.21% |
| May 30, 2024 | James Quigley | Goldman Sachs | $156.00 | $132.68 | 17.58% | 18.18% |
| Apr 12, 2024 | Evan David Seigerman | BMO Capital | $163.00 | $125.40 | 29.98% | 23.48% |
The latest Novo Nordisk stock forecast, released on Sep 11, 2024 by Louise Chen from Cantor Fitzgerald, set a price target of $160.00, which represents a 18.32% increase from the stock price at the time of the forecast ($135.23), and a 21.21% increase from NVO last price ($132.00).
Novo Nordisk Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 5 |
| Avg Price Target | $160.00 | $160.00 | $159.80 |
| Last Closing Price | $132.00 | $132.00 | $132.00 |
| Upside/Downside | 21.21% | 21.21% | 21.06% |
In the current month, the average price target of Novo Nordisk stock is $160.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 21.21% increase as opposed to Novo Nordisk's last price of $132.00. This month's average price target is down 0.00% compared to last quarter, and up 0.13% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 09, 2024 | Cantor Fitzgerald | Outperform | Outperform | Hold |
| Sep 09, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Aug 19, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Aug 19, 2024 | Cantor Fitzgerald | Buy | Buy | Hold |
| Aug 19, 2024 | Guggenheim | Buy | Buy | Hold |
| Aug 08, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 02, 2024 | Jefferies | - | Underperform | Initialise |
| Jul 02, 2024 | Jefferies | Underperform | Underperform | Hold |
Novo Nordisk's last stock rating was published by Cantor Fitzgerald on Sep 11, 2024. The company gave NVO a "Overweight" rating, the same as its previous rate.
Novo Nordisk Financial Forecast
Novo Nordisk Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $53.37B | $48.09B | $45.57B | $41.27B | $42.03B | $38.33B | $35.62B | $33.04B | $33.80B | $32.14B | $30.93B | $30.01B | $33.88B | $32.42B | $30.28B | $30.04B | $29.29B | $29.73B | $27.76B |
| Avg Forecast | $83.30B | $83.54B | $80.84B | $80.27B | $82.37B | $75.17B | $69.28B | $63.38B | $62.03B | $57.80B | $56.03B | $52.46B | $47.28B | $44.89B | $40.76B | $5.77B | $5.76B | $5.39B | $5.16B | $5.21B | $5.20B | $4.88B | $4.76B | $4.65B | $4.74B | $4.50B | $4.42B | $4.35B | $31.30B | $29.13B |
| High Forecast | $86.34B | $86.59B | $83.80B | $83.19B | $85.38B | $76.01B | $71.81B | $65.69B | $64.47B | $59.36B | $58.08B | $54.37B | $49.00B | $46.52B | $40.76B | $5.86B | $5.85B | $5.48B | $5.24B | $5.29B | $5.28B | $4.95B | $4.83B | $4.72B | $4.81B | $4.57B | $4.49B | $4.42B | $37.56B | $34.95B |
| Low Forecast | $81.21B | $81.45B | $78.82B | $78.25B | $80.31B | $74.55B | $67.54B | $61.79B | $59.58B | $56.23B | $54.63B | $51.14B | $46.09B | $43.76B | $40.76B | $5.72B | $5.71B | $5.35B | $5.12B | $5.17B | $5.16B | $4.84B | $4.72B | $4.61B | $4.70B | $4.46B | $4.38B | $4.31B | $25.04B | $23.30B |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 10 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.02% | 1.02% | 1.01% | 7.29% | 6.65% | 6.60% | 6.40% | 6.49% | 6.18% | 6.34% | 6.30% | 7.29% | 6.84% | 6.73% | 6.80% | 6.73% | 0.95% | 0.95% |
Novo Nordisk's average Quarter revenue forecast for Jun 23 based on 1 analysts is $56.03B, with a low forecast of $54.63B, and a high forecast of $58.08B. NVO's average Quarter revenue forecast represents a 5.00% increase compared to the company's last Quarter revenue of $53.37B (Mar 23).
Novo Nordisk EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 10 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $27.58B | $10.31B | $23.80B | $21.68B | $21.01B | $13.81B | $17.39B | $16.13B | $18.11B | $11.68B | $15.10B | $15.09B | $17.41B | $9.52B | $15.03B | $14.58B | $15.31B | $10.72B | $12.60B |
| Avg Forecast | $39.61B | $39.73B | $38.44B | $38.17B | $39.17B | $35.75B | $32.95B | $30.14B | $29.50B | $27.48B | $26.65B | $24.95B | $22.48B | $21.34B | $19.38B | $2.74B | $2.74B | $2.57B | $2.45B | $2.48B | $2.47B | $2.32B | $2.26B | $2.21B | $2.25B | $2.14B | $2.10B | $2.07B | $11.28B | $13.22B |
| High Forecast | $41.06B | $41.18B | $39.85B | $39.56B | $40.60B | $36.14B | $34.15B | $31.24B | $30.66B | $28.23B | $27.62B | $25.86B | $23.30B | $22.12B | $19.38B | $2.78B | $2.78B | $2.60B | $2.49B | $2.52B | $2.51B | $2.36B | $2.30B | $2.24B | $2.29B | $2.17B | $2.13B | $2.10B | $13.54B | $15.86B |
| Low Forecast | $38.62B | $38.73B | $37.48B | $37.21B | $38.19B | $35.45B | $32.12B | $29.38B | $28.33B | $26.74B | $25.98B | $24.32B | $21.92B | $20.81B | $19.38B | $2.72B | $2.72B | $2.54B | $2.43B | $2.46B | $2.45B | $2.30B | $2.24B | $2.19B | $2.23B | $2.12B | $2.08B | $2.05B | $9.03B | $10.57B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 0.46% | 1.11% | 1.12% | 7.66% | 5.04% | 6.78% | 6.57% | 7.31% | 4.72% | 6.51% | 6.67% | 7.88% | 4.22% | 7.03% | 6.94% | 7.40% | 0.95% | 0.95% |
1 analysts predict NVO's average Quarter EBITDA for Jun 23 to be $26.65B, with a high of $27.62B and a low of $25.98B. This is -3.38% lower than Novo Nordisk's previous annual EBITDA (Mar 23) of $27.58B.
Novo Nordisk Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 10 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $19.81B | $13.59B | $14.40B | $13.32B | $14.21B | $10.89B | $12.12B | $12.12B | $12.62B | $9.32B | $10.30B | $10.63B | $11.90B | $8.72B | $10.19B | $9.60B | $10.45B | $8.50B | $9.04B |
| Avg Forecast | $27.30B | $29.67B | $29.66B | $29.36B | $28.37B | $27.56B | $21.92B | $106.74B | $20.28B | $21.48B | $20.67B | $95.74B | $12.99B | $96.43B | $13.03B | $12.71B | $10.59B | $11.51B | $10.69B | $11.78B | $9.18B | $10.53B | $11.22B | $10.67B | $8.72B | $9.87B | $9.60B | $9.77B | $8.94B | $9.48B |
| High Forecast | $28.59B | $31.08B | $31.06B | $30.75B | $29.72B | $29.38B | $22.96B | $128.08B | $20.89B | $22.69B | $21.65B | $114.89B | $13.60B | $115.72B | $13.03B | $15.25B | $12.70B | $13.82B | $12.82B | $14.14B | $11.01B | $12.63B | $13.47B | $12.81B | $10.46B | $11.84B | $11.51B | $11.73B | $10.73B | $11.38B |
| Low Forecast | $26.41B | $28.70B | $28.69B | $28.40B | $27.45B | $26.35B | $21.20B | $85.39B | $19.66B | $20.27B | $19.99B | $76.59B | $12.56B | $77.15B | $13.03B | $10.16B | $8.47B | $9.21B | $8.55B | $9.43B | $7.34B | $8.42B | $8.98B | $8.54B | $6.97B | $7.89B | $7.68B | $7.82B | $7.16B | $7.59B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.21% | 1.05% | 0.15% | 1.02% | 1.12% | 1.03% | 1.05% | 1.13% | 1.07% | 1.02% | 0.98% | 0.95% | 1.11% | 1.00% | 1.03% | 1.00% | 1.07% | 0.95% | 0.95% |
Novo Nordisk's average Quarter net income forecast for Jun 23 is $20.67B, with a range of $19.99B to $21.65B. NVO's average Quarter net income forecast represents a 4.30% increase compared to the company's last Quarter net income of $19.81B (Mar 23).
Novo Nordisk SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 10 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $13.48B | $15.09B | $12.61B | $11.83B | $11.15B | $12.82B | $10.14B | $8.90B | $9.19B | $10.96B | $9.18B | $8.22B | $8.52B | $10.77B | $8.77B | $8.43B | $7.86B | $10.00B | $8.06B |
| Avg Forecast | $23.78B | $23.85B | $23.08B | $22.91B | $23.52B | $21.46B | $19.78B | $18.09B | $17.71B | $16.50B | $16.00B | $14.98B | $13.50B | $12.81B | $11.64B | $1.65B | $1.64B | $1.54B | $1.47B | $1.49B | $1.48B | $1.39B | $1.36B | $1.33B | $1.35B | $1.28B | $1.26B | $1.24B | $10.52B | $8.46B |
| High Forecast | $24.65B | $24.72B | $23.92B | $23.75B | $24.38B | $21.70B | $20.50B | $18.75B | $18.41B | $16.95B | $16.58B | $15.52B | $13.99B | $13.28B | $11.64B | $1.67B | $1.67B | $1.56B | $1.50B | $1.51B | $1.51B | $1.41B | $1.38B | $1.35B | $1.37B | $1.30B | $1.28B | $1.26B | $12.63B | $10.15B |
| Low Forecast | $23.18B | $23.25B | $22.50B | $22.34B | $22.93B | $21.28B | $19.28B | $17.64B | $17.01B | $16.05B | $15.60B | $14.60B | $13.16B | $12.49B | $11.64B | $1.63B | $1.63B | $1.53B | $1.46B | $1.48B | $1.47B | $1.38B | $1.35B | $1.32B | $1.34B | $1.27B | $1.25B | $1.23B | $8.42B | $6.77B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 1.12% | 0.98% | 1.02% | 6.77% | 7.80% | 6.59% | 6.04% | 6.18% | 7.39% | 6.59% | 6.05% | 6.42% | 7.96% | 6.83% | 6.68% | 6.33% | 0.95% | 0.95% |
Novo Nordisk's average Quarter SG&A projection for Jun 23 is $16.00B, based on 1 Wall Street analysts, with a range of $15.60B to $16.58B. The forecast indicates a 18.65% rise compared to NVO last annual SG&A of $13.48B (Mar 23).
Novo Nordisk EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 10 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $8.81 | $6.01 | $6.37 | $5.87 | $6.24 | $4.75 | $5.29 | $5.26 | $5.47 | $4.00 | $4.42 | $4.54 | $5.07 | $3.68 | $4.30 | $4.03 | $4.37 | $3.52 | $3.74 |
| Avg Forecast | $6.11 | $6.64 | $6.64 | $6.58 | $6.35 | $6.17 | $4.91 | $5.22 | $4.54 | $4.81 | $4.63 | $4.26 | $2.91 | $3.10 | $2.91 | $2.85 | $2.34 | $2.49 | $2.45 | $2.55 | $1.83 | $2.23 | $2.27 | $2.36 | $1.86 | $2.06 | $1.98 | $2.02 | $3.74 | $4.09 |
| High Forecast | $6.40 | $6.96 | $6.96 | $6.89 | $6.66 | $6.58 | $5.14 | $5.47 | $4.68 | $5.08 | $4.85 | $4.46 | $3.05 | $3.25 | $2.91 | $2.90 | $2.39 | $2.54 | $2.50 | $2.60 | $1.87 | $2.27 | $2.31 | $2.40 | $1.90 | $2.11 | $2.02 | $2.06 | $4.49 | $4.92 |
| Low Forecast | $5.91 | $6.43 | $6.42 | $6.36 | $6.15 | $5.90 | $4.75 | $5.05 | $4.40 | $4.54 | $4.48 | $4.12 | $2.81 | $3.00 | $2.91 | $2.82 | $2.31 | $2.46 | $2.43 | $2.52 | $1.81 | $2.20 | $2.24 | $2.33 | $1.84 | $2.04 | $1.96 | $2.00 | $2.99 | $3.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 2.07% | 2.07% | 2.05% | 2.01% | 2.19% | 2.03% | 2.13% | 2.15% | 2.14% | 2.19% | 1.98% | 2.00% | 2.15% | 1.98% | 2.08% | 2.03% | 2.16% | 0.94% | 0.91% |
According to 1 Wall Street analysts, Novo Nordisk's projected average Quarter EPS for Jun 23 is $4.63, with a low estimate of $4.48 and a high estimate of $4.85. This represents a -47.47% decrease compared to NVO previous annual EPS of $8.81 (Mar 23).
Novo Nordisk Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.70 | $70.00 | 9900.00% | Buy |
| CVAC | CureVac | $3.28 | $29.00 | 784.15% | Buy |
| NVAX | Novavax | $12.93 | $74.67 | 477.49% | Buy |
| NTLA | Intellia Therapeutics | $22.55 | $119.16 | 428.43% | Buy |
| CRSP | CRISPR Therapeutics | $49.87 | $109.58 | 119.73% | Buy |
| MRNA | Moderna | $71.99 | $148.85 | 106.76% | Hold |
| BMRN | BioMarin Pharmaceutical | $70.55 | $107.74 | 52.71% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.36 | $315.75 | 35.31% | Buy |
| SRPT | Sarepta Therapeutics | $125.69 | $169.93 | 35.20% | Buy |
| BNTX | BioNTech SE | $124.71 | $153.14 | 22.80% | Buy |
| NVO | Novo Nordisk | $132.00 | $159.00 | 20.45% | Buy |
| DNA | Ginkgo Bioworks | $6.81 | $7.34 | 7.78% | Buy |
| TGTX | TG Therapeutics | $25.08 | $26.40 | 5.26% | Buy |
| ALNY | Alnylam Pharmaceuticals | $274.46 | $250.16 | -8.85% | Buy |
| REGN | Regeneron Pharmaceuticals | $1.15K | $952.23 | -16.96% | Buy |
| VRTX | Vertex Pharmaceuticals | $481.26 | $381.05 | -20.82% | Buy |
NVO Forecast FAQ
Is Novo Nordisk a good buy?
Yes, according to 8 Wall Street analysts, Novo Nordisk (NVO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of NVO's total ratings.
What is NVO's price target?
Novo Nordisk (NVO) average price target is $159 with a range of $156 to $160, implying a 20.45% from its last price of $132. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Novo Nordisk stock go up soon?
According to Wall Street analysts' prediction for NVO stock, the company can go up by 20.45% (from the last price of $132 to the average price target of $159), up by 21.21% based on the highest stock price target, and up by 18.18% based on the lowest stock price target.
Can Novo Nordisk stock reach $200?
NVO's average twelve months analyst stock price target of $159 does not support the claim that Novo Nordisk can reach $200 in the near future.
What is Novo Nordisk's current price target trend?
1 Wall Street analyst forecast a $160 price target for Novo Nordisk (NVO) this month, up 21.21% from its last price of $132. Compared to the last 3 and 12 months, the average price target increased by 21.21% and increased by 21.06%, respectively.
What are Novo Nordisk's analysts' financial forecasts?
Novo Nordisk's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $290.21B (high $298.89B, low $284.19B), average EBITDA is $138B (high $142.13B, low $135.14B), average net income is $184.59B (high $210.14B, low $160.39B), average SG&A $82.85B (high $85.33B, low $81.13B), and average EPS is $22.65 (high $23.84, low $21.84). NVO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $327.95B (high $339.92B, low $319.72B), average EBITDA is $155.95B (high $161.64B, low $152.04B), average net income is $115.98B (high $121.49B, low $112.2B), average SG&A $93.63B (high $97.04B, low $91.28B), and average EPS is $25.97 (high $27.21, low $25.13).
Did the NVO's actual financial results beat the analysts' financial forecasts?
Based on Novo Nordisk's last annual report (Dec 2022), the company's revenue was $176.95B, beating the average analysts forecast of $138.69B by 27.59%. Apple's EBITDA was $82.04B, beating the average prediction of $65.95B by 24.40%. The company's net income was $55.52B, missing the average estimation of $135.16B by -58.92%. Apple's SG&A was $50.68B, beating the average forecast of $39.59B by 28.01%. Lastly, the company's EPS was $24.51, beating the average prediction of $11.77 by 108.26%. In terms of the last quarterly report (Mar 2023), Novo Nordisk's revenue was $53.37B, beating the average analysts' forecast of $52.46B by 1.73%. The company's EBITDA was $27.58B, beating the average prediction of $24.95B by 10.55%. Novo Nordisk's net income was $19.81B, missing the average estimation of $95.74B by -79.30%. The company's SG&A was $13.48B, missing the average forecast of $14.98B by -9.97%. Lastly, the company's EPS was $8.81, beating the average prediction of $4.26 by 106.95%